The "map" Doc linked to is really good. It was out together by RA Capital Management. Their discussion of GNBT is a good proxy of what the serious investors really think of us and why we aren't getting any exposure. The only way to get real investment is to show actual progress that teh peptides work. Short of that all the PRs in the world aren't going to get anyone to invest. When the PR goes out that peptides show efficacy then yo can think about backing up the truck and PPS moving north. Here is the short write up by a firm looking in from the outside.


Generex/EpiVax (il-key platform) (Shows GNBT as a Canadian company--If investors cant easily tell we are an American company that's a bad sign)


--Only show the immune system pieces of viral proteins

*This unproven approach involves delivering viral proteins linked with immunostimulatory factors.

*These 2 small companies (gnbt grouped w/ another company ) do not have prior experience developing infectious disease vaccines with their technologies and are not funded to manufacture at scale. Both approaches may trigger T-cell immune responses, which can be complementary to other vaccines (similar to Flow Pharma). This in itself is an unproven approach and neither company states this as their goal.